Aerie Pharmaceuticals (AERI) stock price, revenue, and financials

Aerie Pharmaceuticals market cap is $625.1 m, and annual revenue was $83.14 m in FY 2020

$625.1 M

AERI Mkt cap, 14-Oct-2021

$23 M

Aerie Pharmaceuticals Revenue Q1, 2021
Aerie Pharmaceuticals Gross profit (Q1, 2021)16.3 M
Aerie Pharmaceuticals Gross profit margin (Q1, 2021), %70.8%
Aerie Pharmaceuticals Net income (Q1, 2021)-42 M
Aerie Pharmaceuticals EBIT (Q1, 2021)-34.2 M
Aerie Pharmaceuticals Cash, 31-Mar-2021122.7 M
Aerie Pharmaceuticals EV732.4 M
Get notified regarding key financial metrics and revenue changes at Aerie PharmaceuticalsLearn more
Banner background

Aerie Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

24.2m69.9m83.1m

Cost of goods sold

641.0k22.8m25.3m

Gross profit

23.5m47.1m57.8m

Gross profit Margin, %

97%67%70%

R&D expense

72.1m86.1m91.4m74.0m

General and administrative expense

73.6m120.6m138.4m137.2m

Operating expense total

145.7m233.3m234.6m213.5m

EBIT

(22.2m)(50.0m)(75.1m)(96.9m)(145.7m)(209.7m)(187.5m)(155.7m)

EBIT margin, %

(867%)(268%)(187%)

Interest expense

Pre tax profit

(74.2m)(98.9m)(146.9m)(232.6m)(199.7m)(177.9m)

Income tax expense

139.0k193.0k(1.8m)3.0k(90.0k)5.2m

Net Income

(31.1m)(48.1m)(74.4m)(99.1m)(145.1m)(232.6m)(199.6m)(183.1m)

Aerie Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

69.6m85.6m91.1m197.9m197.6m202.8m143.9m151.6m

Accounts Receivable

399.0m2.7m38.4m56.0m

Prepaid Expenses

4.5m4.5m7.7m8.3m

Inventories

618.0k1.1m1.9m4.0m10.1m21.1m27.1m

Current Assets

70.3m141.0m138.4m237.7m254.1m220.2m376.3m331.8m

PP&E

31.9m60.5m58.1m54.3m

Total Assets

70.5m161.1m159.1m248.3m290.3m285.0m452.6m402.0m

Accounts Payable

3.5m551.0k551.0k551.0k6.2m12.4m12.8m8.8m

Short-term debt

4.9m

Current Liabilities

3.5m8.9m17.1m19.4m25.2m50.8m83.6m104.5m

Long-term debt

12.1m220.6m

Total Debt

12.1m225.5m

Total Liabilities

142.9m154.7m57.2m285.7m378.1m

Common Stock

37.0k45.0k46.0k47.0k

Preferred Stock

Additional Paid-in Capital

162.0m171.3m236.5m422.0m597.3m924.2m1.1b1.1b

Retained Earnings

(143.2m)(217.6m)(316.6m)(461.7m)(696.4m)(896.0m)(1.1b)

Total Equity

67.0m18.8m105.3m135.6m227.8m167.0m24.0m

Financial Leverage

1.1 x8.5 x2.4 x2.1 x1.3 x2.7 x16.8 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

4.6m35.8m27.9m148.9m113.5m100.9m106.9m74.3m58.5m211.9m139.5m242.7m194.1m249.5m270.6m235.0m148.9m109.4m248.7m134.2m151.3m129.8m122.7m

Accounts Receivable

1.1m2.0m14.8m25.7m33.3m42.9m43.1m46.8m46.2m

Prepaid Expenses

117.0k672.0k930.0k656.0k1.2m1.1m1.3m1.4m1.2m2.9m2.4m2.1m2.1m6.1m2.5m3.3m6.5m8.7m7.9m10.5m9.0m9.1m10.9m

Inventories

1.1m5.7m5.6m10.2m10.4m14.7m20.2m19.1m20.8m28.3m

Current Assets

7.1m65.8m57.3m171.7m171.0m159.9m156.6m120.7m108.2m256.5m210.2m310.0m283.4m341.2m295.5m246.8m180.3m154.1m396.7m338.4m313.1m295.2m293.6m

PP&E

114.0k146.0k160.0k228.0k796.0k1.7m2.9m4.0m3.8m4.6m12.5m14.4m19.2m47.8m54.9m58.4m63.0m58.6m58.3m57.2m56.2m55.3m53.3m

Total Assets

7.2m66.0m57.7m173.3m195.2m176.3m175.2m139.2m120.1m265.9m225.4m327.0m306.2m391.0m353.0m309.2m263.1m234.1m479.2m412.3m385.3m366.7m362.7m

Accounts Payable

1.1m1.2m1.5m3.0m3.2m2.1m2.0m3.7m2.3m2.1m2.0m2.2m3.7m6.1m8.8m7.1m11.1m9.1m11.5m9.2m6.7m4.5m6.5m

Short-term debt

5.6m5.3m5.3m4.1m

Current Liabilities

18.1m3.7m4.8m7.0m22.4m18.3m18.5m16.0m14.1m14.1m13.6m13.8m18.6m25.1m28.8m35.0m52.0m61.1m73.0m79.1m83.9m88.6m93.4m

Long-term debt

174.0m12.0m13.2m12.2m204.7m209.7m215.4m226.0m

Total Debt

174.0m12.0m13.2m12.2m210.3m215.0m220.8m230.1m

Total Liabilities

29.6m3.7m4.8m131.1m146.6m142.5m142.8m139.4m137.5m137.6m141.3m141.9m146.9m154.8m158.1m40.6m70.9m78.4m270.0m285.1m295.4m306.6m373.1m

Common Stock

1.0k23.0k24.0k24.0k25.0k25.0k26.0k27.0k27.0k33.0k34.0k36.0k36.0k40.0k40.0k45.0k46.0k46.0k46.0k46.0k47.0k47.0k47.0k

Preferred Stock

Additional Paid-in Capital

1.1m164.0m166.4m168.8m209.1m213.1m229.7m240.2m246.1m415.6m426.6m555.9m562.5m741.0m754.4m913.5m936.5m947.2m1.1b1.1b1.1b1.1b1.1b

Retained Earnings

(84.8m)(101.7m)(113.6m)(126.7m)(160.4m)(179.2m)(197.2m)(240.3m)(263.5m)(287.3m)(342.4m)(370.8m)(403.2m)(504.6m)(559.6m)(645.0m)(744.4m)(791.5m)(840.9m)(945.1m)(993.3m)(1.0b)(1.1b)

Total Equity

(83.7m)62.3m52.9m42.2m48.6m33.9m32.5m(155.0k)(17.4m)128.4m84.1m185.0m159.3m236.3m194.9m268.6m192.2m155.8m209.2m127.2m89.8m60.1m(10.4m)

Financial Leverage

-0.1 x1.1 x1.1 x4.1 x4 x5.2 x5.4 x-898.1 x-6.9 x2.1 x2.7 x1.8 x1.9 x1.7 x1.8 x1.2 x1.4 x1.5 x2.3 x3.2 x4.3 x6.1 x-35 x

Aerie Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(31.1m)(48.1m)(74.4m)(99.1m)(145.1m)(232.6m)(199.6m)(183.1m)

Depreciation and Amortization

64.0k73.0k252.0k970.0k1.4m13.0m34.2m

Accounts Receivable

(2.7m)(35.6m)(17.7m)

Inventories

(9.7m)(10.3m)(5.2m)

Accounts Payable

2.0m551.0k925.0k26.6m28.8m22.5m

Cash From Operating Activities

(16.4m)(33.7m)(55.7m)(79.8m)(93.2m)(152.6m)(150.4m)(64.7m)

Purchases of PP&E

(16.0m)(31.3m)(10.0m)(3.1m)

Cash From Investing Activities

(63.0k)(73.3m)9.4m18.1m(42.8m)20.8m(183.2m)73.2m

Long-term Borrowings

(8.3m)

Cash From Financing Activities

83.2m123.0m51.8m168.6m135.6m137.0m274.8m(859.0k)

Net Change in Cash

(376.0k)5.2m(58.9m)7.6m

Interest Paid

2.2m2.2m2.2m1.8m6.5m5.0m

Income Taxes Paid

600.0k1.8m5.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(20.9m)(6.7m)(18.5m)(31.6m)(17.2m)(36.0m)(54.0m)(22.7m)(45.9m)(69.7m)(25.8m)(54.2m)(86.6m)(40.7m)(95.7m)(181.1m)(48.0m)(95.1m)(144.5m)(49.1m)(97.3m)(137.0m)(42.0m)

Depreciation and Amortization

47.0k15.0k31.0k50.0k24.0k60.0k102.0k223.0k457.0k702.0k291.0k600.0k916.0k487.0k1.1m1.7m564.0k7.1m9.9m8.2m16.5m25.2m8.9m

Accounts Receivable

(1.1m)(2.0m)(12.0m)(22.9m)(30.6m)(4.6m)(4.7m)(8.5m)9.9m

Inventories

(969.0k)(5.5m)(5.3m)33.0k(14.0k)(4.1m)1.0m2.4m915.0k(1.1m)

Accounts Payable

1.0m208.0k1.4m2.3m1.1m(221.0k)2.4m(1.1m)(3.0m)(3.2m)(5.7m)(6.0m)(2.0m)(6.9m)3.0m10.9m(1.3m)8.6m18.6m(4.0m)1.5m6.9m(10.3m)

Cash From Operating Activities

(11.6m)(4.5m)(12.9m)(22.4m)(13.3m)(29.6m)(41.5m)(19.4m)(39.8m)(61.0m)(24.9m)(45.8m)(67.1m)(40.8m)(77.8m)(121.1m)(48.6m)(85.1m)(123.3m)(41.8m)(64.7m)(87.1m)(30.1m)

Purchases of PP&E

(28.0k)(29.0k)(59.0k)(146.0k)(539.0k)(1.1m)(1.9m)(335.0k)(459.0k)(1.4m)(904.0k)(2.6m)(7.1m)(9.1m)(23.0m)(29.4m)(4.9m)(7.1m)(7.9m)(1.2m)(1.7m)(2.5m)(772.0k)

Cash From Investing Activities

(28.0k)(29.4m)(28.9m)(22.6m)6.1m9.3m14.4m2.4m5.1m14.0m(33.6m)(32.2m)(59.6m)(41.5m)13.6m21.7m(4.9m)(7.1m)(105.2m)33.5m73.2m74.2m2.3m

Long-term Borrowings

(8.3m)(8.3m)

Cash From Financing Activities

13.3m65.0k74.0k124.2m35.1m35.6m48.5m128.0k2.2m167.9m48.0k122.7m122.8m134.3m137.3m136.7m(372.0k)(1.2m)274.4m(1.4m)(1.2m)(1.3m)(1.1m)

Net Change in Cash

1.7m(33.8m)(41.8m)79.2m27.9m15.3m21.4m(16.8m)(32.5m)120.9m(58.4m)44.7m(3.9m)51.9m73.1m37.4m(53.9m)(93.5m)45.9m(9.8m)7.4m(14.2m)(28.9m)

Interest Paid

551.0k1.1m1.6m551.0k1.1m1.6m551.0k540.0k1.6m

Income Taxes Paid

469.0k600.0k1.8m1.8m1.8m

Aerie Pharmaceuticals Ratios

USDQ3, 2013

Financial Leverage

-0.1 x

Aerie Pharmaceuticals Employee Rating

3.213 votes
Culture & Values
3
Work/Life Balance
3.2
Senior Management
3
Salary & Benefits
3.5
Career Opportunities
3.2
Source